• 

  Will India get Covid vaccines on Sunday? DCGI BIG announcement expected

  News | January 02, 2021 22:24 IST

  The Drug Controller General of India (DCGI) will address a press conference on Sunday (January 3) at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines.

• 

  Will India get Covid vaccines today? DCGI BIG announcement expected

  India | January 03, 2021 8:21 IST

  The Drug Controller General of India (DCGI) will address a press conference today at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines. The development comes after the government panels recommended — Oxford-AstraZeneca Covishield and Bharat Biotech's Covaxin — for emergency use.

• 

  COVAXIN, India's indigenously developed Covid vaccine recommended for restricted emergency use

  News | January 02, 2021 23:49 IST

  An expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.

• 

  COVAXIN, India's own Covid vaccine recommended for restricted emergency use

  India | January 03, 2021 9:47 IST

  An expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.

• 

  No emergency approval for vaccine maker SII, Bharat Biotech yet | What we know

  India | December 30, 2020 23:15 IST

  The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee and their next meeting will be held on January 1.

• 

  Covaxin can work against mutated coronavirus: Bharat Biotech

  India | December 29, 2020 20:00 IST

  Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman andManaging Director of the city-based vaccine maker Krishna Ella said on Tuesday. 

• 

  India's indigenous vaccine Covaxin has drawn global attention: ICMR

  India | December 25, 2020 10:10 IST

  AIIMS has invited volunteers for the Phase III clinical trial of the indigenously developed COVID-19 vaccine candidate Covaxin for which it is one of the sites.

• 

  COVAXIN: AIIMS seeks volunteers for phase-3 trial; Know how to enroll

  India | December 24, 2020 13:45 IST

  The All India Institute Of Medical Sciences (AIIMS) has invited applications for volunteers, who want to take part in the COVAXIN Phase-3 trial, which was indigenously developed by Bharat Biotech.

• 

  Bharat Biotech, maker of Covaxin, applies for emergency approval, again

  India | December 23, 2020 22:57 IST

  Hyderabad-based Bharat Biotech, which is developing the country's indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday again applied to the Drug Controller General of India for the emergency use authorisation.

• 

  Bharat Biotech's Covaxin shows encouraging results in clinical trials

  India | December 23, 2020 22:40 IST

  Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials.

• 

  Who should take coronavirus vaccine? Bharat Biotech's Chairman answers

  India | December 23, 2020 19:54 IST

  Bharat Biotech is developing Indian own vaccine for coronavirus called Covaxin. Its chairman was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industry body CII.

Advertisement
• 

  Bharat Biotech’s Covid-19 vaccine Covaxin phase-3 trials crosses half-way mark at 13,000 volunteers

  India | December 22, 2020 12:45 IST

  Bharat Biotech on Tuesday announced successful recruitment of 13,000 volunteers and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of first Make in India vaccine candidate, Covaxin across multiple sites in India.

• 

  UNICEF to transport up to 850 tonnes of Covax per month

  World | December 19, 2020 12:23 IST

  United Nations Children's Fund (UNICEF) could potentially transport up to 850 tonnes of Covid-19 vaccines per month in 2021, should such quantities become available, according to a new assessment published on Friday.

• 

  Shortfall in Phase-III Covaxin trial target, can delay rollout: AIIMS doctor

  India | December 18, 2020 13:49 IST

  The rollout of Covid-19 vaccine by Bharat Biotech for the general public may get delayed as the All India Institute of Medical Sciences (AIIMS), where its Phase-III human clinical trial is underway, is struggling to find takers of the trial shots, the official heading the project told IANS.

• 

  Covaxin 'well tolerated' in all dose groups, no serious adverse events in phase 1 trials

  India | December 16, 2020 20:24 IST

  Bharat Biotech's Covaxin was "well-tolerated" in all dose groups, the company said Wednesday as it released interim findings of phase 1 trials.

• 

  Covaxin likely to be available for public use by February end

  Good News | December 08, 2020 21:55 IST

  Covaxin, the COVID vaccine candidate by Hyderabad-based vaccine manufacturer Bharat Biotech Limited, being developed in collaboration with the Indian Council of Medical Research (ICMR), is likely to be available for use of the general public by the end of February 2021, Dr Sanjay Roy, principal investigator (PI) heading its clinical trial at AIIMS, told IANS on Tuesday.

• 

  Bharat Biotech applies for emergency use authorisation for Covaxin

  India | December 07, 2020 21:55 IST

  After vaccine major Serum Institute of India (SII), Bharat Biotech on Monday applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed coronavirus vaccine called Covaxin.

• 

  Phase-3 clinical trials of Covaxin to begin in Chennai's SRM Hospital

  India | December 07, 2020 20:55 IST

  The phase-3 human clinical trial of India's own vaccine for coronavirus, Covaxin will begin at the SRM Medical College Hospital and Research Centre in Chennai.

• 

  Pfizer seeks emergency use nod for its COVID-19 vaccine in India

  News | December 06, 2020 15:00 IST

  Pfizer India has become the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) seeking an emergency use authorisation for its Covid-19 vaccine in the country.

• 

  Antibodies build up after 2 doses, got only first of Covaxin: Anil Vij

  India | December 06, 2020 12:16 IST

  Anil Vij had offered to be the first volunteer in the phase three trials for Covaxin, an indigenous potential vaccine against COVID-19 being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).